FDA Confirms Dexamethasone Safe for Ongoing Generic Approvals
Published Date: 5/6/2026
Notice
Summary
The FDA has decided that Dexamethasone Elixir, 0.5 mg/5 mL, wasn’t taken off the market because of safety or effectiveness problems. This means generic drug makers can keep getting approval to sell their versions, keeping options open for patients and pharmacies. No changes in costs or availability are expected, so everyone can breathe easy!
Analyzed Economic Effects
3 provisions identified: 2 benefits, 1 costs, 0 mixed.
FDA Finds Dexamethasone Not Withdrawn
On May 6, 2026, FDA determined that DEXAMETHASONE (dexamethasone) elixir, 0.5 mg/5 mL, was not withdrawn from sale for reasons of safety or effectiveness. FDA reviewed the files and relevant postmarketing data and found no information indicating the product was withdrawn for safety or effectiveness.
Generic Approvals Can Continue
Because FDA concluded the listed DEXAMETHASONE elixir was not withdrawn for safety or effectiveness, FDA will not begin procedures to withdraw approval of approved ANDAs that refer to this product and may continue to approve new ANDAs that refer to it so long as they meet legal and regulatory requirements. The listed product is ANDA 088254, originally approved July 27, 1983.
Possible Labeling Updates for ANDAs
FDA stated that if it determines labeling for this drug product should be revised to meet current standards, the Agency will advise ANDA applicants to submit such labeling. The product was reported discontinued by Wockhardt Bio AG in a November 16, 2021 letter and a citizen petition was submitted February 4, 2026.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-16728, Gastroenterology-Urology Devices; Reclassification of Diagnostic Endoscopic Light Source Systems To Be Renamed Cystoscopic Systems Intended as an Aid for Detection of Bladder Cancer
The Food and Drug Administration (FDA) is proposing to reclassify diagnostic endoscopic light source systems (product code OAY), which are postamendments class III devices, from class III (premarket approval) into class II (special controls), subject to premarket notification. FDA is also proposing a new device classification regulation with the name "Cystoscopic system intended as an aid for detection of bladder cancer," along with special controls that FDA believes are necessary to provide a reasonable assurance of the safety and effectiveness of these devices.
2026-16712, Agency Information Collection Activities; Proposed Collection; Comment Request; Imports and Electronic Import Entries
The FDA wants your thoughts on how they collect info about imports and electronic import entries. If you’re involved in importing goods, this could affect you! They’re asking for comments by October 16, 2026, to help improve the process without adding extra costs or hassle.
2026-16727, Hematology and Pathology Devices; Reclassification of In Situ Hybridization Test Systems for Use With a Corresponding Approved Oncology Therapeutic Product
The Food and Drug Administration (FDA, the Agency, or we) is issuing a final order reclassifying in situ hybridization (ISH) test systems indicated for use with a corresponding approved oncology therapeutic product (product codes NYQ, MVD, OWE, and PNK), all postamendments class III (premarket approval) devices, into class II (special controls), subject to premarket notification. FDA is also establishing a new device classification regulation, along with the special controls that are necessary to provide a reasonable assurance of safety and effectiveness of this device type.
Previous / Next Documents
Previous: 2026-08936, Public Meeting of the National Volcano Early Warning and Monitoring System Advisory Committee
The National Volcano Early Warning and Monitoring System Advisory Committee is holding a public meeting on June 3-4, 2026, to discuss how to keep people safe from volcanoes. This meeting affects communities near volcanoes, scientists, and policymakers by shaping better volcano monitoring and warning plans. Anyone interested can join in person or online, but you need to register by May 30, 2026.
Next: 2026-08940, Information Collection; Addressing DEI Discrimination by Federal Contractors
Federal contractors will soon need to share info showing they’re fighting discrimination based on diversity, equity, and inclusion (DEI). Four big agencies—DoD, GSA, NASA, and OFPP—are asking for public feedback on this new info collection by July 6, 2026. This effort aims to keep workplaces fair without adding too much paperwork or cost.